HQY vs. CYTK, EXEL, JAZZ, GMED, ENSG, ELAN, PCVX, INSP, MASI, and TNET
Should you be buying HealthEquity stock or one of its competitors? The main competitors of HealthEquity include Cytokinetics (CYTK), Exelixis (EXEL), Jazz Pharmaceuticals (JAZZ), Globus Medical (GMED), The Ensign Group (ENSG), Elanco Animal Health (ELAN), Vaxcyte (PCVX), Inspire Medical Systems (INSP), Masimo (MASI), and TriNet Group (TNET).
HealthEquity (NASDAQ:HQY) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, community ranking, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.
HealthEquity presently has a consensus target price of $96.17, suggesting a potential upside of 19.82%. Cytokinetics has a consensus target price of $79.33, suggesting a potential upside of 21.42%. Given Cytokinetics' higher probable upside, analysts clearly believe Cytokinetics is more favorable than HealthEquity.
Cytokinetics received 259 more outperform votes than HealthEquity when rated by MarketBeat users. Likewise, 79.14% of users gave Cytokinetics an outperform vote while only 69.24% of users gave HealthEquity an outperform vote.
HealthEquity has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.
In the previous week, Cytokinetics had 8 more articles in the media than HealthEquity. MarketBeat recorded 10 mentions for Cytokinetics and 2 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.06 beat Cytokinetics' score of 0.44 indicating that HealthEquity is being referred to more favorably in the media.
HealthEquity has a net margin of 5.57% compared to Cytokinetics' net margin of -6,988.63%. HealthEquity's return on equity of 6.91% beat Cytokinetics' return on equity.
HealthEquity has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.
99.6% of HealthEquity shares are held by institutional investors. 2.7% of HealthEquity shares are held by company insiders. Comparatively, 3.4% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
HealthEquity beats Cytokinetics on 10 of the 18 factors compared between the two stocks.
Get HealthEquity News Delivered to You Automatically
Sign up to receive the latest news and ratings for HQY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HQY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HealthEquity Competitors List
Related Companies and Tools
